Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
Stopped Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical development of autoimmune indications on the subcutaneous delivery.
Conditions
Interventions
- DRUG: Ofatumumab
- DRUG: Placebo
Sponsor
GlaxoSmithKline